Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.

Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events across all dose levels. Initial Phase 1 monotherapy data for ERAS-0015 are ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced an important milestone in the development of ...

The firm said at the JP Morgan Healthcare Conference that a pivotal Phase III study, testing daraxonrasib in RAS-mutant ...

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ...

Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.